KCT0000696尚未招募未知
Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgery
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •normal renal function (serum creatinine < 1.3 mg/dl)
- •-anemic patient (Hgb < 13 g/dl in men, Hgb < 12 g/dl in women accoridng to World Health Organization criteria)
- •-elective surgery
- •-20 years old or more than 20 years old
- •-patient who agree to participate the present clinical study voluntarily
排除标准
- •-non-animic patient ( Hgb = 13 g/dl in men, Hgb = 12 g/dl in women)
- •-uncontrolled hypertension ( diastolic blood presusre > 100 mmHg)
- •-platelet > 450,000/mm3
- •-history of thromboembolism
- •-concomitant cancer
- •-chronic use of erythropoietin
- •-patient who disagree to paricipate the present study voluntarily
- •-emergency surgery
- •-chronic kidney disease or serum creatinine = 1.3 mg/dl
- •-preoperative inotropic support
研究者
相似试验
已完成
4 期
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy.Anemia secondary to chemo and/or radiotherapy.RPCEC00000080Center of Molecular Immunology(CIM)161
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60
已完成
3 期
Erythropoietin efficiency in thalassemiaCondition 1: breast cancer. Condition 2: colon cancer. Condition 3: Rectal cancer. Condition 4: Gastric cancer. Condition 5: Esophageal cancer. Condition 6: Head & Neck cancer. Condition 7: Thalassemia beta minor.Malignant neoplasm of breastMalignant neoplasm of colonMalignant neoplasm of rectumMalignant neoplasm of stomachMalignant neoplasm of esophagusMalignant neoplasm of other and ill-defined sitesThalassemia minorD56.3IRCT20211202053252N1Babol University of Medical Sciences72
已完成
4 期
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338
已完成
不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148